{"id":"havrix-hav","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Injection site soreness"},{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5","effect":"Nausea"}]},"_chembl":null,"_dailymed":{"setId":"f9499a4d-1288-4bd3-9d59-1d72092c38cd","title":"HAVRIX (HEPATITIS A VACCINE) INJECTION, SUSPENSION [GLAXOSMITHKLINE BIOLOGICALS SA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Havrix contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. The vaccine induces the production of anti-HAV antibodies that provide long-term protection against hepatitis A infection. A single dose provides protection in approximately 95% of recipients within 2 weeks, with booster doses extending immunity to 20+ years.","oneSentence":"Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:50.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in adults and children ≥12 months of age"},{"name":"Post-exposure prophylaxis for hepatitis A"}]},"trialDetails":[{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT03654677","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-09-19","conditions":"Hepatitis A Vaccine","enrollment":253},{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT00139113","phase":"PHASE4","title":"Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1996-09","conditions":"Hepatitis A","enrollment":248},{"nctId":"NCT06277882","phase":"PHASE4","title":"Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-02-29","conditions":"Cirrhosis, Hep A, Vaccination","enrollment":50},{"nctId":"NCT03654664","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-06-20","conditions":"Hepatitis A Vaccine","enrollment":119},{"nctId":"NCT05012787","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases","status":"TERMINATED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-11-12","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05613127","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs","status":"UNKNOWN","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2022-12","conditions":"Hepatitis A, Hep A","enrollment":106},{"nctId":"NCT00880893","phase":"PHASE2","title":"Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04-07","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus","enrollment":1198},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT01311024","phase":"","title":"Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage","status":"COMPLETED","sponsor":"Arto Palmu","startDate":"2011-04","conditions":"Pneumococcal Infections","enrollment":2341},{"nctId":"NCT00624819","phase":"PHASE3","title":"Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":524},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT00839254","phase":"PHASE3","title":"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-18","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":6181},{"nctId":"NCT00861380","phase":"PHASE3","title":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":41188},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT02712359","phase":"NA","title":"This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-01","conditions":"Hepatitis A Vaccine","enrollment":1201},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":"Hepatitis B, Hepatitis A","enrollment":596},{"nctId":"NCT00534885","phase":"PHASE4","title":"Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2006-03","conditions":"Hepatitis A","enrollment":400},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":"Infections, Meningococcal","enrollment":1063},{"nctId":"NCT01282216","phase":"PHASE2","title":"Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-04","conditions":"Transplant-Related Cancer","enrollment":120},{"nctId":"NCT01307436","phase":"PHASE3","title":"Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2007-03-14","conditions":"Hepatitis A","enrollment":327},{"nctId":"NCT00128661","phase":"PHASE3","title":"Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-30","conditions":"Cervical Cancer, Precancerous Condition","enrollment":7466},{"nctId":"NCT01037114","phase":"PHASE4","title":"Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-27","conditions":"Hepatitis A, Hepatitis B","enrollment":50},{"nctId":"NCT02583412","phase":"PHASE4","title":"Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-09","conditions":"Meningococcal Serogroup B","enrollment":120},{"nctId":"NCT00224484","phase":"PHASE3","title":"Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-07","conditions":"Herpes Simplex","enrollment":5960},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":"Varicella, Rubella, Mumps","enrollment":1851},{"nctId":"NCT01978093","phase":"PHASE3","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-01","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":600},{"nctId":"NCT01379937","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-28","conditions":"Influenza","enrollment":520},{"nctId":"NCT01000324","phase":"PHASE4","title":"Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-06","conditions":"Hepatitis A, Hepatitis B","enrollment":44},{"nctId":"NCT00057330","phase":"PHASE3","title":"HerpeVac Trial for Young Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01-14","conditions":"Herpes Simplex Infection","enrollment":8323},{"nctId":"NCT00122681","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05-06","conditions":"Infections, Papillomavirus","enrollment":18729},{"nctId":"NCT00197236","phase":"PHASE3","title":"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-11","conditions":"Hepatitis A","enrollment":468},{"nctId":"NCT00684671","phase":"PHASE4","title":"Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-26","conditions":"Hepatitis A, Hepatitis B","enrollment":506},{"nctId":"NCT00197002","phase":"PHASE3","title":"Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-11","conditions":"Hepatitis A","enrollment":521},{"nctId":"NCT01218308","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Influenza","enrollment":5220},{"nctId":"NCT00197015","phase":"PHASE3","title":"Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-06","conditions":"Hepatitis A","enrollment":1474},{"nctId":"NCT00289757","phase":"PHASE4","title":"Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-01","conditions":"Hepatitis A","enrollment":78},{"nctId":"NCT03183492","phase":"PHASE4","title":"Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-05-07","conditions":"Hepatitis A","enrollment":""},{"nctId":"NCT00291876","phase":"PHASE4","title":"Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-01","conditions":"Hepatitis A","enrollment":135},{"nctId":"NCT02038907","phase":"PHASE2","title":"Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-28","conditions":"Healthy Volunteers, Norovirus, Prevention","enrollment":420},{"nctId":"NCT00603252","phase":"PHASE4","title":"Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Hepatitis B, Hepatitis A","enrollment":213},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":"Encephalitis","enrollment":50},{"nctId":"NCT00197249","phase":"PHASE3","title":"Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Hepatitis A","enrollment":1034},{"nctId":"NCT00544271","phase":"PHASE4","title":"Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2003-05","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":720},{"nctId":"NCT01830855","phase":"PHASE3","title":"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Meningococcal Vaccine","enrollment":3596},{"nctId":"NCT01947465","phase":"","title":"Immunogenicity and Safety of Vaccinations in Immunocompromised Persons","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-10","conditions":"Arthritis, Rheumatoid, Spondylarthritis, Vasculitis","enrollment":645},{"nctId":"NCT01360970","phase":"PHASE2","title":"Hepatitis A Vaccine in Patients With Immunomodulating Drugs","status":"COMPLETED","sponsor":"Lars Rombo","startDate":"2009-09","conditions":"Response to Hepatitis A Vaccine","enrollment":68},{"nctId":"NCT02124785","phase":"PHASE4","title":"Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-05","conditions":"Hepatitis A","enrollment":""},{"nctId":"NCT02082639","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-02","conditions":"Infections, Papillomavirus","enrollment":""},{"nctId":"NCT01352793","phase":"PHASE3","title":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Meningitis, Meningococcal","enrollment":5715},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":"Hepatitis A","enrollment":308},{"nctId":"NCT00596271","phase":"PHASE3","title":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":192},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00483470","phase":"PHASE3","title":"Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Hepatitis A","enrollment":720},{"nctId":"NCT01349829","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-03","conditions":"Hepatitis A","enrollment":251},{"nctId":"NCT01252680","phase":"PHASE4","title":"Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2010-04","conditions":"Hepatitis A","enrollment":303},{"nctId":"NCT01102296","phase":"NA","title":"Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-06","conditions":"Hepatitis","enrollment":582},{"nctId":"NCT00316706","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Cervical Intraepithelial Neoplasia, Papillomavirus Infection","enrollment":1245},{"nctId":"NCT00190242","phase":"PHASE3","title":"Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2003-06","conditions":"HIV Infection","enrollment":99},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":27231},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":"Typhoid, Paratyphoid Fever","enrollment":37673}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":784,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Havrix (HAV)","genericName":"Havrix (HAV)","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children ≥12 months of age, Post-exposure prophylaxis for hepatitis A.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}